Annexure 1: Merck Statement on Ivermectin use During the COVID-19 Pandemic, 4 Feb 2021 (pp. 4)

Annexure 2: US Senate Testimony of Dr. Pierre Kory, 6 May 2020 (pp. 5)

Annexure 3: US Senate Testimony of Dr. Pierre Kory, 8 Dec 2020 (pp. 16)

Annexure 4: The BIRD Recommendation on the Use of Ivermectin for Covid-19, 3 Feb 2021 (pp. 107)

Annexure 5: Judge orders Batavia hospital to treat coronavirus patient with Ivermectin, 9 Apr 2021 (pp. 2)

Annexure 6: After experimental Covid-19 treatment, 80-Year-old woman thankful to be home, 22 Feb 2021 (pp. 7)

Annexure 7: US judge orders administration of Ivermectin to comatose patient, 12 May 2021 (pp. 6)

Annexure 8: Front Line COVID-19 Critical Care Alliance Statement on New Guidance on Ivermectin from the All India Institute of Medical Science, 29 Apr 2021 (pp. 1)

Annexure 9: FLCCC BIRD Joint Statement on Widespread Use of Ivermectin in India for Prevention and Early Treatment, 3 May 2021 (pp. 2)

Annexure 10: Therapeutics and COVID-19, WHO Living Guideline, 13 Mar 2021 (pp. 60)

Annexure 11: FLCCC Alliance Statement on the Irregular Actions of PublicHealth Agencies and the Widespread DisinformationCampaign Against Ivermectin, 12 May 2021 (pp. 14)

Annexure 12: AIIMS/ICMR-COVID-19 National Task Force/Joint Monitoring Group (Dte.GHS) Ministry of Health & Family Welfare, Government of India
CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS, 22 Apr 2021 (pp. 1)

Annexure 13: AIIMS/ICMR-COVID-19 National Task Force/Joint Monitoring Group (Dte.GHS) Ministry of Health & Family Welfare, Government of India
CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS, 17 May 2021 (pp. 1)

Annexure 14: Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates, 25 Jan 2021 (pp. 3)